Crescent Biopharma, Inc.

Crescent Biopharma, Inc.

CBIO·NASDAQ

$18.45

+8.5%
HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$508.70M
EPS-14.7800
P/E Ratio-1.25
Earnings Date07/30/2026

cbio

Long Term Debt

Last Annual Value

1.21M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Crescent Biopharma, Inc.

Crescent Biopharma, Inc. Competitors Analysis of Long Term Debt

CBIO · NASDAQ
CompanyLong Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.21M
N/AN/AN/A 
22.40M
-6.4%N/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
13.82M
N/AN/AN/A
1.00M
-58.7%-46.8%N/A
256.92M
46.1%N/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
140.64M
-6.8%-1.2%10.9%
Crescent Biopharma, Inc.

Crescent Biopharma, Inc. Fair Value Envelope

CBIO · NASDAQ

Our analysis suggests that CBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $18.45, this represents a potential HIDDEN relative to our calculated worth for Crescent Biopharma, Inc..

Intrinsic Value
Current Price: $18.45